AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders.
NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate)
abrevaŽ (docosanol 10% cream)
AVP-923 for Pseudobulbar Affect (PBA)
Fiscal 2011 Fourth Quarter and Year End Financial Results Conference Call WebcastDate: Dec 12, 2011Begins: 4:30 pm E.T.
Dec 12, 2011Avanir Pharmaceuticals Reports Fiscal 2011 Fourth Quarter and Year End Financial Results
Dec 06, 2011Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
Nov 22, 2011Avanir Pharmaceuticals to Participate in Piper Jaffray Health Care Conference
NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate)
